ProfileGDS5678 / 1419576_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 47% 46% 45% 46% 46% 45% 46% 46% 47% 48% 47% 46% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3501953
GSM967853U87-EV human glioblastoma xenograft - Control 23.0959747
GSM967854U87-EV human glioblastoma xenograft - Control 33.095146
GSM967855U87-EV human glioblastoma xenograft - Control 42.9875445
GSM967856U87-EV human glioblastoma xenograft - Control 53.0372946
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1875446
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1350445
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0716546
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0561346
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0839447
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1351548
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0653947
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0778846
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0839446